Basel, Switzerland · Founded 2017 · Privately Held (backing)
Developer of novel radiopharmaceutical tracers designed to target cancer diagnostics. Nuclidium is based in Basel, Switzerland and was founded in 2017. Its last reported valuation was $163 million in Jul 2025. It has raised $101 million.
Last reported valuation
$163.2M
Oct 2026
Priced at
—
Total raised
$100.6M
Last round
—
Cap table — not yet on record
Nuclidium's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Nuclidium with a free account
·The complete investor list: 13 names
·Watch Nuclidium: the Monday email on marks, rounds and moves
